Avid Bioservices, Inc.(CDMO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CDMO Avid Bioservices, Inc.

Pre-Market Trading 01-24 07:47:50 EST

12.45

+0.00

0.00%

High12.46	Low12.39	Vol1.96M
Open12.44	D1 Closing12.45	Amplitude0.56%
Mkt Cap796.34M	Tradable Cap630.01M	Total Shares63.96M
T/O24.41M	T/O Rate3.88%	Tradable Shares50.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CDMO","market":"US","secType":"STK","nameCN":"Avid Bioservices, Inc.","latestPrice":12.45,"timestamp":1737666000000,"preClose":12.45,"halted":0,"volume":1964687,"delay":0,"floatShares":50602960,"shares":63963302,"eps":-2.394638,"marketStatus":"Pre-Market Trading","change":0,"latestTime":"01-24 07:47:50 EST","open":12.44,"high":12.46,"low":12.39,"amount":24412803.4862,"amplitude":0.005622,"askPrice":12.49,"askSize":260,"bidPrice":12.41,"bidSize":261,"shortable":3,"etf":0,"ttmEps":-2.394638,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1737729000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.45,"postHourTrading":{"tag":"盘后","latestPrice":12.45,"preClose":12.45,"latestTime":"16:05 EST","volume":13792,"amount":171710.4,"timestamp":1737666344353},"volumeRatio":1.0012007372820069,"impliedVol":0.9857,"impliedVolPercentile":0.728},"requestUrl":"/m/hq/s/CDMO/tweets","defaultTab":"tweets","newsList":[{"id":"2505173099","title":"Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505173099","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505173099?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:40","pubTimestamp":1737632400,"startTime":"0","endTime":"0","summary":"Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts. Raanana, Israel, Jan. 23, 2025  -- Polyrizon Ltd. , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today it has commenced preliminary work related to the Good Manufacturing Practice  manufacturing process for its PL-14 allergy blocker in preparation for its planned 2025 clinical trial. The company works closely with Eurofins CDMO, having recently entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S.Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material  requirements, ensuring high-quality production and compliance with regulatory standards.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-commences-gmp-manufacturing-preliminary-114000593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTM","PLRZ","BK4134","BK4123","CDMO","PL","BK4139"],"gpt_icon":0},{"id":"2505706614","title":"Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706614","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706614?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:05","pubTimestamp":1737579900,"startTime":"0","endTime":"0","summary":"Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to StockholdersTUSTIN, Calif., Jan.  22, 2025  (GLOBE NEWSWIRE) -- Avid Bioservices","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/22/3013870/0/en/Avid-Reminds-Stockholders-to-Vote-Today-FOR-the-Transaction-with-GHO-and-Ampersand.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOR","BK4024","CDMO","BK4139"],"gpt_icon":0},{"id":"2505672713","title":"Avid Bioservices (CDMO) Started a Sale Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2505672713","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505672713?lang=en_us&edition=fundamental","pubTime":"2025-01-22 23:55","pubTimestamp":1737561349,"startTime":"0","endTime":"0","summary":"Laughing Water Capital, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, Class A interests in Laughing Water Capital returned about 18.6% bringing year-to-date returns to approximately 39.5%. The SP500TR and R2000 returned 2.4% and 0.3% in the quarter and 25% and 11.5% year-to-date, respectively. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.Avid Bioservices, Inc.  is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Avid Bioservices, Inc.  at the end of the third quarter which was 26 in the previous quarter. While we acknowledge the potential of Avid Bioservices, Inc.  as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promisin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avid-bioservices-cdmo-started-sale-155549593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","QID","USJW.SI","TQQQ","NQmain","CDMOP","SQQQ",".IXIC","MNQmain","NVIW.SI","CDMO","PSQ","TSYW.SI","USAW.SI","BK4139"],"gpt_icon":1},{"id":"2505667740","title":"BioHarvest Announces Appointment of Sharon Malka to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2505667740","media":"Newsfile","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505667740?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:30","pubTimestamp":1737552600,"startTime":"0","endTime":"0","summary":"Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the Board. Vancouver, British Columbia and Rehovot, Israel-- - BioHarvest Sciences Inc.,    , a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately.\"We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors,\" said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division. \"His operational experience in advancing innovative technologies, and in structuring strategic transactions and major financing rounds, will be invaluable to BioHarvest in our current and future growth stages.\". \"Sharon is a veteran capital markets and technology executive, whose perspective and experience will be very valuable as we scale our Botanical Synthesis technology and expand our operat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioharvest-announces-appointment-sharon-malka-133000734.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioharvest-announces-appointment-sharon-malka-133000734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","BK4139","CDMO","BHST"],"gpt_icon":0},{"id":"2505487740","title":"Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™","url":"https://stock-news.laohu8.com/highlight/detail?id=2505487740","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505487740?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:30","pubTimestamp":1737552600,"startTime":"0","endTime":"0","summary":"Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs. DURHAM, N.C., Jan. 22, 2025  -- Scorpius Holdings, Inc  , an integrated contract development and manufacturing organization , today announced its collaboration with KaloCyte, a pioneering pre-clinical company in the field of therapeutic innovation. Under this initial project, Scorpius will utilize its scientific and technical expertise to enhance manufacturing efficiencies for KaloCyte’s lead candidate, ErythroMer, a dried, bio-inspired artificial red blood cell designed to address life-threatening blood loss in situations where stored red blood cells are unavailable, unsuitable, or in short supply. The two companies are also evaluating opportunities to establish a commercial-scale manufacturing agreement.KaloCyte is a pre-clinical biotech therapeutic startup company developing ErythroMer, a bioengineered artificial red blood cell  substitute that can be freeze-dried for long-term storage and is e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scorpius-holdings-announces-collaboration-kalocyte-133000012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4139","LU2065731478.USD","RBC","CDMO","IE00BLDYK493.USD","SCPX","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2505793188","title":"Press Release: Samsung Biologics reports fourth quarter and fiscal year 2024 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2505793188","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505793188?lang=en_us&edition=fundamental","pubTime":"2025-01-22 15:06","pubTimestamp":1737529560,"startTime":"0","endTime":"0","summary":"--  Recorded Q4'24 consolidated revenue of KRW 1.26 trillion. --  Recorded FY'24 consolidated revenue of KRW 4.55 trillion. --  Poised for further growth with expanded capacity and new service. INCHEON, South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics , a global contract development and manufacturing organization , today announced financial results for the fourth quarter and fiscal year 2024.\"2024 has been a year of steady progress for Samsung Biologics as we expanded collaboration with both pharma and biotech companies, supported by our focus on operational and quality excellence,\" said John Rim, CEO and President of Samsung Biologics. \"We have been able to continue delivering on our commitments by investing in capacity, modality, and geographic expansion. We expect another year of growth through the opening of Plant 5, launch of ADC services, and continued investment in innovative technologies and sustainability. These efforts will enable us to better address the evolving","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","BK4099","03160","BK4555","TM","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2505278301","title":"Avid Bioservices says ISS, Glass Lewis recommend vote ‘FOR’ transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2505278301","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505278301?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:27","pubTimestamp":1737466040,"startTime":"0","endTime":"0","summary":"Avid Bioservices (CDMO) announced that leading independent proxy advisory firms Institutional Shareholder Services and Glass Lewis & Co. recommend ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avid-bioservices-says-iss-glass-lewis-recommend-vote-for-transaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avid-bioservices-says-iss-glass-lewis-recommend-vote-for-transaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDMO","BK4139","CDMOP","BK4024","FOR"],"gpt_icon":0},{"id":"2505275672","title":"Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and Ampersand","url":"https://stock-news.laohu8.com/highlight/detail?id=2505275672","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505275672?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:00","pubTimestamp":1737464400,"startTime":"0","endTime":"0","summary":"Leading Independent Proxy Advisory Firms Recognize the Significant, Immediate and Certain Cash Value the Transaction Delivers to Avid Stockholders. TUSTIN, Calif., Jan. 21, 2025  -- Avid Bioservices, Inc.  , a dedicated biologics contract development and manufacturing organization  working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that leading independent proxy advisory firms Institutional Shareholder Services  and Glass Lewis & Co.  recommend that Avid stockholders vote “FOR” the Company’s pending transaction with GHO Capital Partners LLP  and Ampersand Capital Partners .Nick Green, president and CEO ofAvid Bioservices, said, “We are pleased that ISS and Glass Lewis recognize the premium value of the GHO and Ampersand transaction for Avid stockholders, as well as the process run by our Board of Directors to ensure we are maximizing value. We encourage our stockholders to vote","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avid-recommends-stockholders-recommendations-iss-130000644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4024","FOR","CDMO","BK4139"],"gpt_icon":0},{"id":"2505291212","title":"ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2505291212","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505291212?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"ST. PAUL, Minn., Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex Grant. The G-Rex Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma , an incurable type of pediatric brain tumor. BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025 for the treatment of children and young adults with DIPG.\"G-Rex has been an essential element of our clinical CAR-T manufacturing program at Seattle Children's dating back to 2012. We greatly appreciate the support of ScaleReady's G-Rex Grant Program as well as the technical expertise offered to us by ScaleReady related to new advancements,\" said Dr. Michael Jensen, Chief Scientific Officer at BrainChild Bio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/scaleready-announces-g-rex-grant-120000458.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scaleready-announces-g-rex-grant-120000458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","BK4121","BK4585","BK4588","IE00B19Z6F94.USD","IE00B64QTZ34.USD","TECH","CDMO","IE0034390439.USD","BK4139","BK4022","BK4230","REXX"],"gpt_icon":0},{"id":"2504611062","title":"Lifecore Biomedical Announces Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2504611062","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504611062?lang=en_us&edition=fundamental","pubTime":"2025-01-18 06:24","pubTimestamp":1737152640,"startTime":"0","endTime":"0","summary":"Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock TermsCHASKA, Minn., Jan.  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/17/3011726/23089/en/Lifecore-Biomedical-Announces-Special-Stockholder-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","CDMO","BK4212","LFCR","CFO"],"gpt_icon":0},{"id":"2504119395","title":"Scorpius Holdings Cancels Planned Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2504119395","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504119395?lang=en_us&edition=fundamental","pubTime":"2025-01-18 04:13","pubTimestamp":1737144780,"startTime":"0","endTime":"0","summary":"DURHAM, N.C., Jan.  17, 2025  (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/17/3011680/32418/en/Scorpius-Holdings-Cancels-Planned-Reverse-Stock-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO"],"gpt_icon":0},{"id":"2504086940","title":"Press Release: Scorpius Holdings Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2504086940","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504086940?lang=en_us&edition=fundamental","pubTime":"2025-01-17 05:05","pubTimestamp":1737061500,"startTime":"0","endTime":"0","summary":"DURHAM, N.C., Jan. 16, 2025  -- Scorpius Holdings, Inc  , an integrated contract development and manufacturing organization , today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split  of the Company's common stock , to increase the selling price of the Company's Common Stock in order to maintain compliance with the requirements and policies of the NYSE American.The Reverse Stock Split will take legal effect at 12:01 A.M. Eastern Time on January 21, 2025, and the Company's Common Stock will open for trading on the NYSE American on January 21, 2025, on a post-split basis, under the existing ticker symbol \"SCPX\" but with a new CUSIP number 42237K607.This release contains forward-looking statements within the meaning of the Private Securities Litigat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","SCPX"],"gpt_icon":0},{"id":"2503361202","title":"HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503361202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503361202?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:00","pubTimestamp":1736942400,"startTime":"0","endTime":"0","summary":"MIRAMAR, Fla., Jan. 15, 2025  -- HCW Biologics Inc. , , a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic inflammation and disease, announced today that Hing C. Wong, PhD., Founder and CEO, will serve as a panelist on Panel Discussion II of the 2025 GenScript Biotech Global Forum as a thought leader regarding Conquering Cell and Gene Therapy  Challenges in Biomanufacturing and Supply Chain Management. The event is taking place on January 15, 2025, alongside the 2025 J.P. Morgan Healthcare Conference in San Francisco.Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics Inc.Conquering CGT’s Challenges in Biomanufacturing and Supply Chain Management. About HCW Biologics:HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade infl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hcw-biologics-founder-ceo-address-120000814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1162221912.USD","BK4127","LU0795875169.SGD","LU1989772840.SGD","BK4504","LU1548497426.USD","LU1720051017.SGD","LU2357305700.SGD","LU0320765646.SGD","LU1732799900.SGD","LU1989772923.USD","LU2028103732.USD","BK4516","CDMO","BK4581","BK4139","BK4539","BK4534","LU0106261372.USD","LU0098860793.USD","LU0006306889.USD","LU0912757837.SGD","LU1732800096.USD","LU2347655156.SGD","LU1363072403.SGD","LU2023251221.USD","LU0795875086.SGD","LU2089283258.USD","BK4585","HCWB","LU2271345857.HKD","LU0225283273.USD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU0314104364.USD","LU0158827948.USD","LU0971096721.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU2089284900.SGD","LU0267386448.USD","LU1668664300.SGD","LU2111349929.HKD","LU0158827781.USD","LU0106831901.USD","BK4588"],"gpt_icon":0},{"id":"2503582359","title":"Press Release: Alcami Announces CEO Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2503582359","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503582359?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:12","pubTimestamp":1736784720,"startTime":"0","endTime":"0","summary":"Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries. DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation , a leading contract development and manufacturing organization , today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran.\"On behalf of the Board, I'd like to express gratitude to Bill for his leadership over the last two years during a critical time of facilities expansion and a global supply chain realignment. He was a strong advocate for our clients and the organization benefited from his leadership. I am personally grateful for his contributions and wish him all the best in his new opportunity,\" commented Walsh.Mr. Walsh served as CEO of Alcami on two previous occasions and has served as Chairman over the last four years. In a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIP","BK4007","CDMO"],"gpt_icon":0},{"id":"2503309062","title":"Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309062","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309062?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008443/0/en/Cabaletta-Bio-Outlines-Strategic-Priorities-and-Anticipated-Key-Milestones-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0971096721.USD","ACR","BK4006","LU2089284900.SGD","LU2023251221.USD","BK4585","LU0158827781.USD","IE00B7SZL793.SGD","BK4534","LU1720051108.HKD","IE00BKVL7J92.USD","LU2347655156.SGD","LU0158827948.USD","LU0795875169.SGD","LU0267386448.USD","LU1720051017.SGD","IE00B19Z4B17.USD","LU1732800096.USD","BK4516","LU0320765646.SGD","LU1732799900.SGD","LU1668664300.SGD","LU2111349929.HKD","CDMO","LU0106261372.USD","LU0006306889.USD","LU1074936037.SGD","LU0098860793.USD","BK4588","LU0225283273.USD","LU2271345857.HKD","IE00B66KJ199.SGD","LU2357305700.SGD","LU1989772840.SGD","CABA","BK4127","BK4139","BK4581","CRS","LU0912757837.SGD","LU2028103732.USD","LU2065731478.USD","LU0314104364.USD","LU1989772923.USD","LU2089283258.USD","LU0106831901.USD","LU1363072403.SGD","IE00BZ1G4Q59.USD","IE0031619046.USD"],"gpt_icon":0},{"id":"2503390630","title":"Healios Expands ProcellCure Function to Include Contract Manufacturing Service","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390630","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390630?lang=en_us&edition=fundamental","pubTime":"2025-01-13 06:58","pubTimestamp":1736722718,"startTime":"0","endTime":"0","summary":"Healios (TYO:4593) has added a Contract Development and Manufacturing Organization (CDMO) function to its subsidiary, ProcellCure, according to a Friday filing on the Tokyo Stock Exchange.The move aim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2502383350","title":"Healios Expands ProcellCure’s Capabilities with CDMO Role","url":"https://stock-news.laohu8.com/highlight/detail?id=2502383350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502383350?lang=en_us&edition=fundamental","pubTime":"2025-01-10 15:53","pubTimestamp":1736495598,"startTime":"0","endTime":"0","summary":"Healios KK ( ($JP:4593) ) has issued an announcement. Healios K.K. announced the expansion of its subsidiary ProcellCure’s role by incorporating a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-expands-procellcures-capabilities-with-cdmo-role?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-expands-procellcures-capabilities-with-cdmo-role?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2502003760","title":"RBC Capital Sticks to Its Hold Rating for Avid Bioservices (CDMO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502003760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502003760?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:51","pubTimestamp":1736473904,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Sean Dodge maintained a Hold rating on Avid Bioservices (CDMO – Research Report) on January 8 and set a price target of $12.50....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-avid-bioservices-cdmo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-avid-bioservices-cdmo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDMO","CDMOP"],"gpt_icon":0},{"id":"2502972510","title":"Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2502972510","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502972510?lang=en_us&edition=fundamental","pubTime":"2025-01-09 19:00","pubTimestamp":1736420400,"startTime":"0","endTime":"0","summary":"Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in San FranciscoMILAN and NEW YORK, Jan.  09, 2025  (GLOBE NEWSWIRE) -- Genenta ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3006902/0/en/Genenta-Strengthens-Agreement-with-AGC-Biologics-to-Boost-Cell-Therapy-Manufacturing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","BK4139","GNTA"],"gpt_icon":0},{"id":"2502702089","title":"Press Release: Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand","url":"https://stock-news.laohu8.com/highlight/detail?id=2502702089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502702089?lang=en_us&edition=fundamental","pubTime":"2025-01-09 06:15","pubTimestamp":1736374500,"startTime":"0","endTime":"0","summary":"Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand. Avid Urges Stockholders to Vote FOR the Pending Transaction TODAY. TUSTIN, Calif., Jan. 08, 2025  -- Avid Bioservices, Inc.  , a dedicated biologics contract development and manufacturing organization  working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Capital Partners LLP  and Ampersand Capital Partners  on its investor relations website.-- The transaction with GHO and Ampersand delivers significant, immediate. -- The transaction presents a significant premium to the Company's. share price across multiple time periods, including a 63.8%. premium to its closing price on June 4, 2024, the last trading day. -- The robust implied multiples exceed the trading multiples of all. -- The transaction deli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","CDMOP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avidbio.com","stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":0.0155},{"period":"3month","weight":0.245},{"period":"6month","weight":0.217},{"period":"1year","weight":0.8864},{"period":"ytd","weight":0.0081}],"compareEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.053},{"period":"6month","weight":0.12},{"period":"1year","weight":0.2562},{"period":"ytd","weight":0.0404}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.244975},{"month":2,"riseRate":0.566667,"avgChangeRate":0.058259},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.035156},{"month":4,"riseRate":0.4,"avgChangeRate":-0.032334},{"month":5,"riseRate":0.516129,"avgChangeRate":0.109027},{"month":6,"riseRate":0.419355,"avgChangeRate":0.007765},{"month":7,"riseRate":0.322581,"avgChangeRate":0.039463},{"month":8,"riseRate":0.354839,"avgChangeRate":0.002481},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.046446},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.040707},{"month":11,"riseRate":0.548387,"avgChangeRate":0.073378},{"month":12,"riseRate":0.419355,"avgChangeRate":0.023819}],"exchange":"NASDAQ","name":"Avid Bioservices, Inc.","nameEN":"Avid Bioservices, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avid Bioservices, Inc.(CDMO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avid Bioservices, Inc.(CDMO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avid Bioservices, Inc.,CDMO,Avid Bioservices, Inc.股票,Avid Bioservices, Inc.股票老虎,Avid Bioservices, Inc.股票老虎国际,Avid Bioservices, Inc.行情,Avid Bioservices, Inc.股票行情,Avid Bioservices, Inc.股价,Avid Bioservices, Inc.股市,Avid Bioservices, Inc.股票价格,Avid Bioservices, Inc.股票交易,Avid Bioservices, Inc.股票购买,Avid Bioservices, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avid Bioservices, Inc.(CDMO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avid Bioservices, Inc.(CDMO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction